From: Site-specific analysis of gene expression in early osteoarthritis using the Pond-Nuki model in dogs
p value | ACL-X | Control | CrMFC | CrLFC | ACL-X | Control | p value |
---|---|---|---|---|---|---|---|
<0.05 | 11.1 ± 1.71 | 0.57 ± 0.27 | COL 1 | MMP 13 | 0.096 ± 0.061 | 0.006 ± 0.002 | <0.05 |
<0.05 | 859 ± 229 | 298 ± 212 | Aggrecan | COX-2 | 0.017 ± 0.012 | 0.001 ± 0.001 | <0.05 |
<0.05 | 0.075 ± 0.032 | 0 ± 0 | MMP 13 |  |  |  |  |
<0.05 | 0.106 ± 0.092 | 0.001 ± 0.001 | COX-2 |  |  |  |  |
<0.05 | 50.8 ± 18.8 | 16.8 ± 11.9 | TIMP-1 |  |  |  |  |
<0.05 | 10.4 ± 6.8 | 0.744 ± 0.224 | MMP 3 |  |  |  |  |
0.0555 | 0.853 ± 0.714 | 0.01 ± 0.006 | ADAMTS 5 |  |  |  |  |
p value | ACL-X | Control | CaMFC | CaLFC | ACL-X | Control | p value |
<0.05 | 709 ± 659 | 4.32 ± 0.35 | COL 1 | Aggrecan | 370 ± 262 | 98 ± 23 | <0.05 |
<0.05 | 1.224 ± 1.189 | 0.006 ± 0.001 | MMP 13 |  |  |  |  |
<0.05 | 0.009 ± 0.005 | 0.001 ± 0.001 | COX-2 |  |  |  |  |
<0.05 | 0.055 ± 0.028 | 0.016 ± 0.013 | ADAMTS 5 |  |  |  |  |